At a glance

ClinicalIndex Comparison Record

Phase 4Completed· 16 enrolled

Drug / intervention

0.25 mg alprazolam +2 moredrug

Likely dose

0.25 mg alprazolamfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00703885

NCT00703885Phase 4Completed

Compare CT.gov

PharmacofMRI of Anxiolytic Medications (Alprazolam)

University of California, San Diego·interventional·Posted Jun 24, 2008·Updated Dec 22, 2014

In Brief

A Phase 4 clinical trial evaluating 0.25 mg alprazolam, 1.0 mg alprazolam, and 1 other intervention for Anxiety Disorders. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The purpose of this study is to use functional magnetic resonance imaging (fMRI) in healthy controls to examine the acute effects of certain anxiolytic medications on brain function.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsAnxiety Disorders

CountriesUnited States

CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished

20082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartJan 2008

First PostedJun 2008

Primary CompletionAug 2008

TodayJul 2026

First PostedJun 24, 2008

Enrollment StartJan 1, 2008

Primary CompletionAug 1, 2008

TodayJul 2, 2026

Enrollment to primary: 7 monthsPosted 18.0 years ago

Interventions

0.25 mg alprazolamdrug

0.25 mg alprazolam PO (liquid) to be administered 1 hour prior to fMRI scan Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.

1.0 mg alprazolamdrug

1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.

placebodrug

Placebo (liquid) to be administered 1 hour prior to fMRI scan Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.